Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate

Pamela Pineda, Aaron Kanter, R S Mc Ivor, Stephen J. Benkovic, Andre Rosowsky, Carston R Wagner

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Two double (F31A/F34A, I60A/L67G) and one quadruple (F31A/F34A/I60A/L67G) mutant murine dihydrofolate reductases were constructed and evaluated for their ability to impart antifolate resistance. Both I60A/L67G and F31A/F34A/I60A/L67G were found to be unstable and devoid of catalytic activity. The Ki values for F31A/F34A, methotrexate (MTX), bis-MTX, and PT-523 were found to be 10100-, 4410-, and 617-fold higher than the wild-type enzyme, respectively, but only 13.5-fold higher for trimetrexate (TMTX). These findings suggest that F31A/F34A could be used for gene therapy to render normal cells resistant to MTX but sensitive to TMTX.

Original languageEnglish (US)
Pages (from-to)2816-2818
Number of pages3
JournalJournal of Medicinal Chemistry
Volume46
Issue number14
DOIs
StatePublished - Jul 3 2003

Fingerprint

Trimetrexate
Tetrahydrofolate Dehydrogenase
Methotrexate
Folic Acid Antagonists
Genetic Therapy
Enzymes

Cite this

Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. / Pineda, Pamela; Kanter, Aaron; Mc Ivor, R S; Benkovic, Stephen J.; Rosowsky, Andre; Wagner, Carston R.

In: Journal of Medicinal Chemistry, Vol. 46, No. 14, 03.07.2003, p. 2816-2818.

Research output: Contribution to journalArticle

Pineda, Pamela ; Kanter, Aaron ; Mc Ivor, R S ; Benkovic, Stephen J. ; Rosowsky, Andre ; Wagner, Carston R. / Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate. In: Journal of Medicinal Chemistry. 2003 ; Vol. 46, No. 14. pp. 2816-2818.
@article{a244a2507e5b41faa403afccc50bb7f1,
title = "Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate",
abstract = "Two double (F31A/F34A, I60A/L67G) and one quadruple (F31A/F34A/I60A/L67G) mutant murine dihydrofolate reductases were constructed and evaluated for their ability to impart antifolate resistance. Both I60A/L67G and F31A/F34A/I60A/L67G were found to be unstable and devoid of catalytic activity. The Ki values for F31A/F34A, methotrexate (MTX), bis-MTX, and PT-523 were found to be 10100-, 4410-, and 617-fold higher than the wild-type enzyme, respectively, but only 13.5-fold higher for trimetrexate (TMTX). These findings suggest that F31A/F34A could be used for gene therapy to render normal cells resistant to MTX but sensitive to TMTX.",
author = "Pamela Pineda and Aaron Kanter and {Mc Ivor}, {R S} and Benkovic, {Stephen J.} and Andre Rosowsky and Wagner, {Carston R}",
year = "2003",
month = "7",
day = "3",
doi = "10.1021/jm034057i",
language = "English (US)",
volume = "46",
pages = "2816--2818",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "14",

}

TY - JOUR

T1 - Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate

AU - Pineda, Pamela

AU - Kanter, Aaron

AU - Mc Ivor, R S

AU - Benkovic, Stephen J.

AU - Rosowsky, Andre

AU - Wagner, Carston R

PY - 2003/7/3

Y1 - 2003/7/3

N2 - Two double (F31A/F34A, I60A/L67G) and one quadruple (F31A/F34A/I60A/L67G) mutant murine dihydrofolate reductases were constructed and evaluated for their ability to impart antifolate resistance. Both I60A/L67G and F31A/F34A/I60A/L67G were found to be unstable and devoid of catalytic activity. The Ki values for F31A/F34A, methotrexate (MTX), bis-MTX, and PT-523 were found to be 10100-, 4410-, and 617-fold higher than the wild-type enzyme, respectively, but only 13.5-fold higher for trimetrexate (TMTX). These findings suggest that F31A/F34A could be used for gene therapy to render normal cells resistant to MTX but sensitive to TMTX.

AB - Two double (F31A/F34A, I60A/L67G) and one quadruple (F31A/F34A/I60A/L67G) mutant murine dihydrofolate reductases were constructed and evaluated for their ability to impart antifolate resistance. Both I60A/L67G and F31A/F34A/I60A/L67G were found to be unstable and devoid of catalytic activity. The Ki values for F31A/F34A, methotrexate (MTX), bis-MTX, and PT-523 were found to be 10100-, 4410-, and 617-fold higher than the wild-type enzyme, respectively, but only 13.5-fold higher for trimetrexate (TMTX). These findings suggest that F31A/F34A could be used for gene therapy to render normal cells resistant to MTX but sensitive to TMTX.

UR - http://www.scopus.com/inward/record.url?scp=0038460886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038460886&partnerID=8YFLogxK

U2 - 10.1021/jm034057i

DO - 10.1021/jm034057i

M3 - Article

C2 - 12825924

AN - SCOPUS:0038460886

VL - 46

SP - 2816

EP - 2818

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 14

ER -